What is Talquetamab and why is it important for Myeloma patients?

Talquetamab is a breakthrough drug for Myeloma, an incurable blood cancer. Its approval on the NHS provides a vital new treatment option for patients.

How many patients will benefit from the new drug approval in the UK?

Up to 800 patients in the UK are expected to benefit from the general availability of Talquetamab on the NHS each year.

What impact does this drug have on Sue Harley's life?

Sue Harley, who has Myeloma, states the drug allows her to live her life as if she doesn't have cancer, offering hope and the ability to plan future activities.

Home / Health / Grandmother's Cancer Hope as New Drug Approved

Grandmother's Cancer Hope as New Drug Approved

19 Nov

•

Summary

Breakthrough drug for incurable blood cancer now on NHS.
Up to 800 patients annually could benefit from Talquetamab.
Patient Sue Harley feels she can live life without cancer.

Grandmother's Cancer Hope as New Drug Approved

A groundbreaking drug, Talquetamab, previously only accessible through manufacturer schemes, is now available on the NHS, offering renewed hope to Sue Harley, a grandmother from Birmingham. Harley, diagnosed with incurable Myeloma in 2017, has been in remission for two years after receiving the treatment via a compassionate use program.

Her successful treatment and advocacy have contributed to the drug's general approval by health commissioners. This decision is expected to benefit up to 800 patients annually, providing them with a vital treatment option that allows them to live more normal lives and plan for the future.

The availability of Talquetamab marks a significant advancement in treating blood cancers like Myeloma, which is the third most common type. Consultant haematologist Guy Pratt highlighted the drug's role in improving patients' quality of life, expressing gratitude for its accessibility to all Myeloma patients.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.